
    
      The study will investigate the antidepressant effects of a range of doses of JNJ-42847922
      (seltorexant) (versus placebo), as adjunctive treatment to antidepressant drugs for treatment
      of MDD, and will assess the safety and tolerability of JNJ-42847922. The study will be
      conducted in 3 phases: a screening phase (up to 4 weeks), a double-blind treatment phase (6
      weeks), and a post-treatment follow-up phase (2 weeks). Efficacy, safety, pharmacokinetic,
      and biomarker evaluations will be performed in the study at defined timepoints. The duration
      of the study will be up to approximately 12 weeks (84 days).
    
  